Molecular marker for osteoporosis and application of marker
A technology for osteoporosis and products, applied in the treatment, LYPD3 gene in the field of diagnosis of osteoporosis, can solve the problem of not being able to screen patients with osteoporosis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0064] Example 1 Differential expression of LYPD3 gene in blood
[0065] 1. Research objects:
[0066] Randomly select patients who are about to undergo marrow joint replacement surgery to detect bone density, select 50 patients with osteoporosis, and 40 patients with normal bone density control group (traumatic fracture, no osteoporosis detected), aged 50-70 years. Questionnaire surveys the subjects’ lifestyle and health status.
[0067] Inclusion criteria for patients with osteoporosis: (1) Those who meet the diagnostic criteria for osteoporosis, refer to the "Chinese Osteoporosis Recommended Diagnostic Criteria (Second Draft); (2) All patients have informed consent.
[0068] Exclusion criteria for patients with osteoporosis: those with secondary osteoporosis.
[0069] 2. Extraction of total RNA from blood
[0070] Use Biotech blood RNA extraction kit to extract total RNA from blood
[0071] (1) Take 250μl (or 0.25g) of whole blood into the RNase-Free filter column, centrifuge at 13000...
Embodiment 2
[0105] Example 2 Differential expression of LYPD3 gene in bone tissue
[0106] 1. Research objects:
[0107] Randomly select patients who are about to undergo marrow joint replacement surgery to detect bone density, select 50 patients with osteoporosis, and 40 patients with normal bone density control group (traumatic fracture, no osteoporosis detected), aged 50-70 years. Questionnaire surveys the subjects’ lifestyle and health status.
[0108] Inclusion criteria for patients with osteoporosis: (1) Those who meet the diagnostic criteria for osteoporosis, refer to the "Chinese Osteoporosis Recommended Diagnostic Criteria (Second Draft); (2) All patients have informed consent.
[0109] Exclusion criteria for patients with osteoporosis: those with secondary osteoporosis.
[0110] 2. Obtaining RNA from bone tissue
[0111] From the human femoral head removed from the marrow joint replacement, 1g of hard bone was taken and quickly stored in liquid nitrogen. Trizol is used in the laboratory ...
Embodiment 4
[0130] Example 4 Inhibition of LYPD3 gene expression
[0131] 1. Experiment grouping:
[0132] The experiment is divided into four groups: negative control group (siRNA-NC), siRNA1-LYPD3 group, siRNA2-LYPD3 group, siRNA3-LYPD3 group.
[0133] 2. siRNA design and synthesis
[0134] SiRNA was designed and synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.
[0135] siRNA1-LYPD3:
[0136] The sense strand is 5'-AUUUAUGUGCCAGAAACUGAU-3' (SEQIDNO.7);
[0137] The antisense strand is 5'-CAGUUUCUGGCACAUAAAUGC-3' (SEQIDNO.8),
[0138] siRNA2-LYPD3:
[0139] The sense strand is 5'-AAUUAAAUCUUUAUUGAGGCA-3' (SEQIDNO.9);
[0140] The antisense strand is 5'-CCUCAAUAAAGAUUUAAUUAC-3' (SEQIDNO.10),
[0141] siRNA3-LYPD3:
[0142] The sense strand is 5'-AGUAAUUAAAUCUUUAUUGAG-3' (SEQIDNO.11);
[0143] The antisense strand is 5'-CAAUAAAGAUUUAAUUACUUU-3' (SEQIDNO.12),
[0144] Negative control siRNA sequence (siRNA-NC):
[0145] The sense strand is 5'-CGUACGCGGAAUACUUCGA-3' (SEQIDNO.13);
[0146] The ant...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com